自体造血干细胞移植治疗多发性骨髓瘤临床疗效分析
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i1.11852
Abstract
自体造血干细胞移植是一种利用患者自身造血干细胞重建正常造血和免疫功能的治疗手段。本文聚焦于自体造血干细胞移植在多发性骨髓瘤治疗中的应用,探讨了其作用机制、治疗效果、优势以及潜在风险和并发症。自体造血干细胞移植技术能够有效清除多发性骨髓瘤病灶,恢复患者的造血功能,降低复发风险,并延长生存期。然而,自体造血干细胞移植也可能引发感染、出血等不良反应,需要在治疗过程中加以重视。
Keywords
自体造血干细胞移植；多发性骨髓瘤；临床疗效；治疗机制；复发风险
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 魏依昕,张连生,李莉娟,等.多发性骨髓瘤骨病微环境改变与治疗进展[J].中国免疫学杂志,2024,40(5):1010-1015.
[2] 赵艺涵,孙旭杭,赵琳,等.外泌体miRNA治疗多发性骨髓瘤的作用与机制[J].中国组织工程研究,2025,29(31):6743-6752.
[3] 秦小琪,夏玲,牛园满,等.初诊多发性骨髓瘤血小板减少患者临床特征及预后分析[J].中国肿瘤临床,2024,(12):607-610.
[4] 陶怡,糜坚青.2023年美国国立综合癌症网络(NCCN)《多发性骨髓瘤指南》(第2版)更新解读[J].诊断学理论与实践,2023,22(2):121-126.
[5] DIMOPOULOSMA,MOREAUP,TERPOSE,etal.Multiplemyeloma:EHA-ESMOClinicalPracticeGuidelinesfordiagnosis,treatmentandfollow-up?[J].AnnOncol,2021,32(3):309-322.
[6] 自体造血干细胞移植规范[J].中国医药生物技术,2022,17(1):75-93.
[7] 李诗文,刘卓刚.自体造血干细胞移植后血液重建影响因素研究进展[J].现代肿瘤医学,2021,29(2):358-361.
[8] 郝牧,邱录贵.多发性骨髓瘤肿瘤生物学研究进展[J].中国细胞生物学学报,2022,44(1):111-119.
[9] AL HAMED R,BAZARBACHI AH,MALARD F, et al. Current status of autologous stem cell transplantation for multiple myeloma[J].Blood Cancer J,2019,9 (4):44.
[10] MAQBOOL S,BALOCH MF,KHAN MAK,et al.Autologous hema topoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various disea ses[J].World J Transplant,2024,14(1):87532.
[11] VISRAM A,BREDESON C,ALLAN D, et al. Long term graft function following autologous hematopoietic cell transplant ation and the impact of preemptive plerixafor in predicted poor mobilizers[J].Blood Cancer J,2018,8(1):14.
[12] 杨丽萍,卢馨怡,王鑫炜.新药时代多发性骨髓瘤住院患者感染的临床特征及危险因素分析 [J].中国实验血液学杂志,2024,第32卷(6):1790-1797.
[13] 张天钰,周双白,李青峰.干细胞冷冻保护剂的研究进展[J].组织工程与重建外科杂志,2019,第15卷(6):425-427.
[14] 王荣孝,李建英,邢江涛.新改良外周血造血干细胞冷冻技术的临床应用观察[J].世界最新医学信息文摘,2016,(7):72,71.
[15] 富浩轩,付华来,王捷.气相液氮罐内温度差异对脐带血造血干细胞保存质量的影响[J].临床输血与检验,2021,23(1):50-54.
[16] KUMAR SK,CALLANDER NS,ADEKOLA K,et al.Multiple Myel oma, Version 2.2024,NCCN Clinical Practice Guidelines in Oncol ogy[J].J Natl Compr Canc Netw,2023,21(12):1281-1301.
[17] 中国医师协会血液科医师分会,中华医学会血液学分会.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,61(5):480-487.
[18] 贾静,陈文明,耿传营.VRD耐药多发性骨髓瘤患者的临床特征及预后分析[J].肿瘤,2023,第43卷(9):701-709.
[19] CAVO M,GAY F,BEKSAC M,et al.Autologous haematopoie tic stem-cell transplantation versus bortezomib melphalanprednisone,with or without bortezomib-lenalidomide-dexame thasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):a multic entre,randomised,open-label,phase 3 study[J].Lancet Haematol,2020,7(6):e456-e468.
[20] PERROT A,LAUWERS-CANCES V,CAZAUBIEL T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial[J].Blood,2020,136:39.
[21] RICHARDSON PG,JACOBUS SJ,WELLER EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma[J].N Engl J Med,2022,387(2):132-147.
[22] 高锦宏,高大.自体造血干细胞移植治疗多发性骨髓瘤的进展[J].中国医学前沿杂志(电子版),2024,第16卷(9):26-32,7.
[23] 王宁方,赵崇山,尤月明.多发性骨髓瘤患者骨髓单核细胞免疫表型特点及其临床意义[J].中国实验血液学杂志,2024,第32卷(6):1781-1789.
[24] GOLDSCHMIDT H,BAERTSCH MA,SCHLENZKA J, et al. Salva ge autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase Ⅲ trial Re LApsE[J].Leukemia,2021,35(4):1134-1144.
[25] COOK G,ROYLE KL,O'CONNOR S,et al.The impact of cytoge netics on duration of response and overall survival in patientswith relapsed multiple myeloma(long-term follow-up results from BSBMT/UKMF Myeloma X Relapse[Intensive]):a randomised, open-label,phase 3 trial[J].Br JHaematol,2019,185(3):450-467.
[2] 赵艺涵,孙旭杭,赵琳,等.外泌体miRNA治疗多发性骨髓瘤的作用与机制[J].中国组织工程研究,2025,29(31):6743-6752.
[3] 秦小琪,夏玲,牛园满,等.初诊多发性骨髓瘤血小板减少患者临床特征及预后分析[J].中国肿瘤临床,2024,(12):607-610.
[4] 陶怡,糜坚青.2023年美国国立综合癌症网络(NCCN)《多发性骨髓瘤指南》(第2版)更新解读[J].诊断学理论与实践,2023,22(2):121-126.
[5] DIMOPOULOSMA,MOREAUP,TERPOSE,etal.Multiplemyeloma:EHA-ESMOClinicalPracticeGuidelinesfordiagnosis,treatmentandfollow-up?[J].AnnOncol,2021,32(3):309-322.
[6] 自体造血干细胞移植规范[J].中国医药生物技术,2022,17(1):75-93.
[7] 李诗文,刘卓刚.自体造血干细胞移植后血液重建影响因素研究进展[J].现代肿瘤医学,2021,29(2):358-361.
[8] 郝牧,邱录贵.多发性骨髓瘤肿瘤生物学研究进展[J].中国细胞生物学学报,2022,44(1):111-119.
[9] AL HAMED R,BAZARBACHI AH,MALARD F, et al. Current status of autologous stem cell transplantation for multiple myeloma[J].Blood Cancer J,2019,9 (4):44.
[10] MAQBOOL S,BALOCH MF,KHAN MAK,et al.Autologous hema topoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various disea ses[J].World J Transplant,2024,14(1):87532.
[11] VISRAM A,BREDESON C,ALLAN D, et al. Long term graft function following autologous hematopoietic cell transplant ation and the impact of preemptive plerixafor in predicted poor mobilizers[J].Blood Cancer J,2018,8(1):14.
[12] 杨丽萍,卢馨怡,王鑫炜.新药时代多发性骨髓瘤住院患者感染的临床特征及危险因素分析 [J].中国实验血液学杂志,2024,第32卷(6):1790-1797.
[13] 张天钰,周双白,李青峰.干细胞冷冻保护剂的研究进展[J].组织工程与重建外科杂志,2019,第15卷(6):425-427.
[14] 王荣孝,李建英,邢江涛.新改良外周血造血干细胞冷冻技术的临床应用观察[J].世界最新医学信息文摘,2016,(7):72,71.
[15] 富浩轩,付华来,王捷.气相液氮罐内温度差异对脐带血造血干细胞保存质量的影响[J].临床输血与检验,2021,23(1):50-54.
[16] KUMAR SK,CALLANDER NS,ADEKOLA K,et al.Multiple Myel oma, Version 2.2024,NCCN Clinical Practice Guidelines in Oncol ogy[J].J Natl Compr Canc Netw,2023,21(12):1281-1301.
[17] 中国医师协会血液科医师分会,中华医学会血液学分会.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,61(5):480-487.
[18] 贾静,陈文明,耿传营.VRD耐药多发性骨髓瘤患者的临床特征及预后分析[J].肿瘤,2023,第43卷(9):701-709.
[19] CAVO M,GAY F,BEKSAC M,et al.Autologous haematopoie tic stem-cell transplantation versus bortezomib melphalanprednisone,with or without bortezomib-lenalidomide-dexame thasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):a multic entre,randomised,open-label,phase 3 study[J].Lancet Haematol,2020,7(6):e456-e468.
[20] PERROT A,LAUWERS-CANCES V,CAZAUBIEL T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial[J].Blood,2020,136:39.
[21] RICHARDSON PG,JACOBUS SJ,WELLER EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma[J].N Engl J Med,2022,387(2):132-147.
[22] 高锦宏,高大.自体造血干细胞移植治疗多发性骨髓瘤的进展[J].中国医学前沿杂志(电子版),2024,第16卷(9):26-32,7.
[23] 王宁方,赵崇山,尤月明.多发性骨髓瘤患者骨髓单核细胞免疫表型特点及其临床意义[J].中国实验血液学杂志,2024,第32卷(6):1781-1789.
[24] GOLDSCHMIDT H,BAERTSCH MA,SCHLENZKA J, et al. Salva ge autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase Ⅲ trial Re LApsE[J].Leukemia,2021,35(4):1134-1144.
[25] COOK G,ROYLE KL,O'CONNOR S,et al.The impact of cytoge netics on duration of response and overall survival in patientswith relapsed multiple myeloma(long-term follow-up results from BSBMT/UKMF Myeloma X Relapse[Intensive]):a randomised, open-label,phase 3 trial[J].Br JHaematol,2019,185(3):450-467.
Copyright © 2025 陈城, 高思奇, 吴清扬, 王明鑫, 王琳
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
